GlassScriptPhysician profile
Paula Szczepanczyk
NPI 1487096129
$779.74
in general payments reported to CMS, 2019-2025
22 companies · $118 in 2025
The $118 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $324 · 2020: $42.85 · 2022: $89.41 · 2023: $147 · 2024: $59.32 · 2025: $118.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $324.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $323.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $104.01 | 2019-2025 | Mounjaro, Zepbound |
| Novo Nordisk INC | $75.61 | 2019-2025 | Wegovy, Ozempic |
| Abbott Laboratories | $59.47 | 2019-2020 | |
| Amgen INC. | $55.05 | 2019-2025 | Tepezza |
| Insulet Corporation | $47.47 | 2019-2022 | |
| Beta Bionics, INC. | $43.97 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Bayer Healthcare Pharmaceuticals INC. | $38.40 | 2023-2025 | |
| Tandem Diabetes Care, INC. | $38.36 | 2023-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Sanofi-Aventis U.S. LLC | $38.21 | 2019-2020 | |
| Horizon Therapeutics Plc | $32.10 | 2019-2023 | Tepezza |
| Amarin Pharma, INC. | $30.81 | 2019 | |
| Medtronic, INC. | $28.26 | 2023 | Minimed 780g, Intellis Adaptivestim |
| Senseonics, Incorporated | $28.00 | 2019 | |
| Grt US Holding, INC. | $22.77 | 2022 | |
| Mannkind Corporation | $20.90 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amryt Pharma Holdings LTD | $20.49 | 2022 | |
| Abbvie INC. | $18.28 | 2023 | Synthroid |
| Corcept Therapeutics | $17.22 | 2019 | |
| Alexion Pharmaceuticals, INC. | $16.45 | 2023 | Strensiq |
| Esperion Therapeutics, INC. | $15.94 | 2023 | Nexletol |
| Companion Medical, INC. | $14.56 | 2019 | |
| Dexcom, INC. | $13.41 | 2023 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paula Szczepanczyk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.